Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8728-8736

  Ricart, Alejandro D ^a   Hammond, Lisa A ^a   Kuhn, John G ^b   Takimoto, Chris H ^a   Goetz, Andrew ^a   Forouzesh, Bahram ^a   Forero, Leonardo ^a   Ochoa Bayona, Jose L ^a   Berg, Kristin ^a   Tolcher, Anthony W ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); CISPLATIN; DEXAMETHASONE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; MANNITOL; MITOMYCIN C; NITROSOUREA; ONDANSETRON; PROCHLORPERAZINE; REBECCAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG SOLUBILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOMAGNESEMIA; INFECTION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 29344437247     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1572     Document Type: Article

References (27)

1. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo) 1987;40: 668-78.
2. Anizon F, Belin L, Moreau P, et al. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem 1997;40:3456-65.
3. Pereira ER, Belin L, Sancelme M, et al. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 1996;39:4471-7.
4. Moreau P, Anizon F, Sancelme M, et al. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J Med Chem 1998;41:1631-40.
5. Division of Cancer Treatment, National Cancer Institute. Rebeccamycin analogue NSC 655649 investigator's brochure. Bethesda (MD): National Cancer Institute; 2002.
6. Krishnan BS, Moore ME, Lavoie CP, et al. Fluorescence polarization studies of the binding of BMS 181176 to DNA. J Biomol Struct Dyn 1994;12:625-36.
7. Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 1997;36:3917-29.
8. Bailly C, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M, Waring MJ. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol Pharmacol 1998;53:77-87.
9. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr Med Chem Anti-Canc Agents 2002;2:255-66.
10. Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD. In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors. J Pediatr Hematol Oncol 1998;20:136-9.
11. Dowlati A, Hoppel CL, Ingalls ST, et al. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 2001;19:2309-18.
12. Tolcher AW, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001;19:2937-47.
13. Merchant J, Tutsch K, Dresen A, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res 2002;8:2193-201.
14. Dowlati A, Posey J, Ramanathan R, et al. Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. Proc Am Soc Clin Oncol 2003;22:267.
15. Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ, Bertram JS, Kowalski D. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells. Exp Cell Res 1985;158:1-14.
16. 2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003;5:295-300.
17. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalate antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7.
18. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and In vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-90.
19. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10.
20. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88:734-41.
21. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-84.
22. deJonge MJ, Loos WJ, Gelderblom H, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 2000;18:2104-15.
23. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84: 1201-3.
24. Rowinsky EK, Grochow LB, Sartorius SE, et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:1224-35.
25. de Wit R, Verweij J, Bontenbal M, et al. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst 1996;88:1393-8.
26. Takimoto C, LoRusso PM, Forera L, et al. A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. [abstract A 149]. Prog Proc AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2003:86.
27. Sevak R, DeLaCruz P, Kosiba I, Kuhn J. Characterization of the human cytochrome F450 (CYP450) isozymes involved in the metabolism of rebeccamycin analog (NSC 655649). Proc Am Assoc Cancer Res 2004;45:487.